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Abstract
Moderate to severe chronic graft-versus-host disease (cGVHD) is associated with high morbidity, hospital dependency and 
poor quality of life. In this study, we analyzed a well-defined consecutive series of 98 patients with acute myelogenous leu-
kemia/myelodysplastic syndrome (AML/MDS) who received allogeneic stem cell transplantation with non-myeloablative 
(NMA) conditioning to determine risk factors associated with the severity of cGVHD. cGVHD was defined according to 
the 2005 National Institute of Health consensus criteria. Transfusions before transplantation, presence of HLA antibodies, 
composition of the graft (CD3+, CD19+, CD34+ cells), sibling or matched unrelated donor, female donor to male recipient, 
CMV serology and the development of acute GVHD (aGVHD), were considered potential risk factors. Multivariate Cox 
regression analysis identified the number of CD19+  106/kg (HR 2.79; 95% CI 1.35–5.74), CD3+  106/kg (HR 2.18; 95% 
CI 1.04–4.59) infused cells and the presence of patient HLA antibodies before transplantation (HR 2.34; CI 1.11–4.95) as 
significant risk factors for the development of moderate to severe cGVHD. In summary, we identified in a small, but well-
defined cohort, 3 risk factors associated with the severity of cGVHD that should be validated in a larger multi-center study.
Keywords Risk factors · Moderate to severe · Chronic graft-versus-host disease · Non-myeloablative · PBSCT
Introduction
AlloSCT is a standard treatment for patients with AML/
MDS with high risk of relapse [1–3]. Around 30–70% of 
transplanted patients who are treated with non-myeloablative 
conditioning and receive a T-repleted graft collected from 
peripheral blood develop chronic graft-versus-host disease 
[4–6]. Moderate to severe cGVHD is associated with high 
morbidity, hospital dependency and poor quality of life as 
compared to mild cGVHD [6, 7]. Patients who develop mod-
erate to severe cGVHD are treated with high-dose systemic 
steroids for months and often years, whereas mild cGVHD 
can be treated with topical steroids [8, 9]. Long-term ster-
oid treatment impairs immune function and can, therefore, 
increase the risk of opportunistic infections. Other steroid 
therapy-related complications include osteoporosis, avascu-
lar necrosis, glucose intolerance, cataract, muscle atrophy, 
hypertension, and disturbance of mood and sleep [10].
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Until now, multiple studies have identified risk factors 
associated with the development of cGVHD [5, 11, 12], but 
only a few studies have been carried out to identify risk fac-
tors associated with the severity of cGVHD [6, 13]. Known 
risk factors associated with the development of cGVHD 
independently of the severity of cGVHD are: female donor 
to male recipient, HLA mismatch, peripheral blood as a 
source of stem cells, high numbers of infused T cells, recipi-
ent age, positive CMV serology and antecedent acute GVHD 
[5, 11, 12, 14]. Risk factors which are published to be associ-
ated with the severity of cGVHD are: transplantation from 
an immuned female donor to a male recipient, antecedent 
of aGVHD, CML and NMA conditioning, but most of these 
factors were identified in the context of bone marrow used 
as graft source instead of peripheral blood.
Because moderate to severe cGVHD is associated with 
high morbidity and reduced quality of life and most of the 
stem cell transplants nowadays use peripheral blood as graft 
source, it is relevant to identify risk factors that are associ-
ated with the development of moderate to severe cGVHD in 
patients who undergo peripheral blood AlloSCT.
Materials and methods
Setting and data collection
This retrospective single center cohort study was conducted 
at the University Medical Center Groningen (UMCG), the 
Netherlands. The UMCG is a JACIE accredited tertiary 
academic hospital that performs all the allogeneic stem cell 
transplantations in the North of the Netherlands. We identi-
fied a homogeneous, consecutive cohort of patients, treated 
from July 2003 to September 2015 in our center. Patient 
data were collected from the UMCG transplantation data-
base “ProMise”, and from the UMCG digital patient data-
base. Diagnosis and grading of cGVHD (mild, moderate or 
severe) were done according to clinical manifestations and 
the global severity score based on the consensus criteria of 
the National Institutes of Health (NIH) 2005 [15]. Classifi-
cation of cGVHD was conducted by the treating physician.
Treatment protocol
Patients who were included in the study received their 
AlloSCT between July 16th 2003 and September 4th 2015. 
Inclusion criteria were: (1) adult patients with AML or MDS 
who underwent peripheral blood AlloSCT with NMA con-
ditioning, (2) who had received their first AlloSCT without 
subsequent lymphocyte infusion therapy, (3) had survived 
at least + 90 days, (4) did not relapse within + 100 days and 
5) who developed cGVHD within + 400 days. The last cri-
terion was chosen to identify risk factors that influence the 
incidence of moderate to severe cGVHD at an early stage 
and to reduce long-term treatment effects that could bias the 
outcome of this study. Clinical characteristics of the patients 
are summarized in Table 1. We defined a control group with 
the cohort of patients who did not develop cGVHD or who 
developed only mild cGVHD, versus the cohort of patients 
who developed moderate to severe cGVHD (Table 2).
Chemotherapy regimens before transplantation consisted 
of induction with idarubicin (12 mg/m2 iv) and cytarabine 
(200 mg/m2 iv) with or without G-CSF (5 ug/kg sc), fol-
lowed by consolidation with amsacrine (120 mg/m2 iv) and 
cytarabine (1000 mg/m2 iv).
Non-myeloablative conditioning consisted of fludarabine 
(30 mg/m2 iv days -4 until -2) and total body irradiation 
(2 Gy, day -1) in 85% of patients (appendix Table 1). Proph-
ylaxis for GVHD consisted of cyclosporine (CsA) started 
on day -3 (twice daily 5 mg/kg) and mycophenolate mofetil 
(MMF) started on day 0 (twice daily 15 mg/kg oral) [16]. 
MMF was stopped at day + 28 or gradually tapered after day 
+ 40 depending on the type of donor (SIB or MUD, respec-
tively) and CsA was gradually tapered after day + 100 in the 
absence of GVHD. Acute GVHD grade II was treated as first 
line with systemic prednisolone 1–2 mg/kg/day and thera-
peutic doses of CsA. Chronic GVHD was treated as first 
line with local therapy as mild (0.1% triamcinolone cream, 
tacrolimus cream, dexamethasone 0.01% suspension) or with 
prolonged schedule of systemic prednisolone (1 mg/kg/day) 
progressively tapered over 1 year, in combination with a 
calcineurin inhibitor in case of moderate to severe cGVHD.
All patients were transplanted with a 10/10 matched SIB 
or MUD, except 4 patients. One of these 4 patients was 
transplanted with a 9/10 HLA-A mismatched SIB (patient 
homozygous on A locus) and three patients were trans-
planted with a 9/10 mismatched MUD (2 A mismatched 
and 1 DQB1 mismatched). None of the patients transplanted 
with a mismatched donor had HLA antibodies against the 
mismatched locus. Matching was performed using standard 
high-resolution typing of HLA-A, B, C, DRB1, and DQB1. 
All patients were typed for HLA-DPB1 and the DPB1 T Cell 
epitope algorithm was used to determine permissiveness of 
the combinations [17].
The number of cells in the graft (CD3+, CD19+, CD34+) 
was determined using fluorescence-activated cell sorting. 
Patient serum samples collected before transplantation were 
examined on HLA class I and class II IgG antibody reactiv-
ity using complement-dependent cytotoxicity and/or bead 
array (Lifescreen de luxe or LSA, Immucor). HLA antibody 
positivity was determined according to the manufacturer.
Risk factors
Three categories of risk factors were analyzed for associa-
tion with the development of moderate to severe cGVHD: 
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Table 1  Patient and disease 
characteristics
GVHD graft-versus-host disease, HLA human leukocyte antigen, CMV cytomegalovirus, Flu fludarabine, 
TBI total body irradiation, MUD matched unrelated donor, CsA cyclosporine, MMF mycophenolate mofetil
a HLA antibodies found prior to transplantation in the serum
No cGVHD and mild cGVHD 
(n = 60)
Moderate to severe 






 < 50 15/60 (25%) 9/38 (24%)
 ≥ 50 45/60 (75%) 29/38 (76%)
Donor age
 < 50 33/60 (55%) 23/38 (60%)
 ≥ 50 27/60 (45%) 15/38 (40%)
Donor/patient transplant
 ♂♂ 19/60 (32%) 10/38 (26%)
 ♂♀ 18/60 (30%) 4/38 (10%)
 ♀♀ 12/60 (20%) 10/38 (26%)
 ♀♂ 11/60 (18%) 14/38 (38%)
Transfusions
 < 76 49/58 (84%) 34/36 (94%)
 ≥ 76 9/58 (16%) 2/36 (6%)
Recipient HLA antibodies  positivea 6/60 (10%) 11/38 (29%)
CMV positive donor/recipient 52/60 (87%) 34/38 (89%)
CMV positive donor 32/60 (53%) 20/38 (53%)
CMV positive recipient 48/60 (80%) 24/38 (63%)
Risk at diagnosis
 Low risk 1/60 (2%) 1/37 (3%)
 Moderate risk 28/60 (47%) 22/37 (59%)
 Poor risk/very poor risk 31/60 (51%) 14/37 (38%)
Conditioning
 Flu/TBI 52/60 (92%) 31/38 (82%)
 Other 8/60 (8%) 7/38 (18%)
Remission prior to transplantation
 Complete remission 53/60 (88%) 32/38 (84%)
 No remission 5/60 (8%) 5/38 (13%)
 Persisting aplasia after chemotherapy 2/60 (4%) 1/38 (3%)
Type of transplant
 Sibling 34/60 (57%) 19/38 (50%)
 MUD 26/60 (43%) 19/38 (50%)
HLA match
 10/10 MUD 33/60 (55%) 17/38 (45%)
 9/10 MUD 1/60 (2%) 2/38 (5%)
 Sibling 26/60 (43%) 19/38 (50%)
 DPB1
 Match 40/60 (66%) 23/38 (60%)
 Permissive 10/60 (17%) 8/38 (21%)
 Non-permissive 10/60 (17%) 7/38 (19%)
GVHD prophylaxis
 CsA/MMF 56/60 (94%) 32/38 (8%)
 Other 4/60 (7%) 6/38 (16%)
Infused cells Median (range) Median (range)
 CD3+  106/kg 246.8 (80.0–573.0) 303.6 (140.2–642.6)
 CD19+  106/kg 55.6 (12.0–131.3) 70.4 (18.0–333.5)
 CD34+  106/kg 6.6 (2.2–18.5) 6.4 (2.6–13.5)
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(1) pre-transplantation factors: recipient: age, number of 
transfusions before transplantation, presence of HLA IgG 
antibodies and HLA-DPB1; (2) donor-related factors: age, 
composition of the graft (CD3+, CD19+, CD34+ cells), 
type of donor, female donor to male recipient and positive 
CMV serology; (3) post-transplantation factor: development 
of aGVHD.
Statistical analysis
To describe patients and their disease, patients were strati-
fied on the main outcome: no to mild cGVHD versus mod-
erate to severe cGVHD. Time started at the date of trans-
plantation and ended when moderate or severe cGVHD 
occurred. Death or relapse was a censoring event unless 
moderate or severe cGVHD was present before death or 
relapse. A cutoff Q75 was selected to quantify the effect of 
the donor-infused cells on the development of moderate to 
severe cGVHD. Univariate Cox regression analyses were 
performed to estimate time to the development of moderate 
to severe cGVHD. In this way, hazard ratios (HRs) and 95% 
confidence intervals (95% Cis) were provided. In the multi-
variable stepped forward Cox Regression analyses, all inde-
pendent variables that contributed statistically significantly 
to the univariate analysis (P < 0.20) were entered. To correct 
for any confounding effect from SIB or MUD transplantation 
on the outcome, the type of transplant source was added to 
the multivariate Cox regression model. Risk factors with 
a P value < 0.05 were considered statistically significant. 
Comparing clinical characteristics between patients accord-
ing to the identified risk factors were performed using the 
independent t test and Fisher’s exact test. Relapse and treat-
ment-related mortality were calculated using Kaplan–Meier 
and comparisons were done by log-rank test. Analyses were 
performed in SPSS 22.
Results
A total of 100 consecutive patients fulfilled the inclusion 
criteria for this study. Two patients were excluded from 
this cohort due to missing data (Fig. 1). The final study 
cohort comprised 98 patients, 85 with AML and 13 with 
MDS. Median patient age at the time of transplantation 
was 57 years (range 24–74) and median donor age was 
45 years (range 19–71). Clinical characteristics of the 
patients are summarized in Table 1.
In our cohort, 65/98 (67%) patients developed cGVHD, 
27 patients developed mild cGVHD and 38 patients devel-
oped moderate to severe cGVHD. The median time from 
transplantation to onset of mild cGVHD was 208 days 
(26–398). Onset of mild cGVHD was: de novo (no prior 
aGVHD) in 17 (63%), quiescent (prior aGVHD, but not 
currently active) in 3 (11%) patients, and progressive (pro-
gression from aGVHD to cGVHD) in 7 (26%) patients. 
The most frequent organ involvement in patients who 
developed mild cGVHD was mouth (100%), followed by 
eyes (15%) and skin (15%). Overall cGVHD severity dis-
tribution is described in Table 2. The median time from 
transplantation to onset of moderate to severe cGVHD 
was 208  days (54–380). Onset of moderate to severe 
cGVHD was: de novo in 26 (68%) patients, quiescent in 2 
(5%) patients, and progressive in 10 (27%) patients. The 
most frequent organ involvement in patients who devel-
oped moderate to severe cGVHD was mouth in 37 (97%) 
patients, followed by skin in 29 (76%) and eyes in 21 
(55%) patients. Other affected organs were liver in 37%, 
joints in 18%, gastrointestinal tract (GI) in 18%, genital/
urologic tract in 10%, and lungs in 8% of the patients. 
The median number of organs involved in moderate to 
severe cGVHD was 3 per patient. The organ distribution 
Table 2  cGVHD distribution
No cGVHD and mild 





 Grade I 5/60 (8%) 4/38 (10%)
 Grade II–IV 18/60 (30%) 8/38 (20%)
Chronic GVHD
 Mild 27/60 (45%) –
 Moderate – 27/38 (71%)




6/60 (10%) 2/38 (5%)
 Relapse 15/60 (25%) 2/38 (5%)
 Other 2/60 (3%) –
Fig. 1  Cohort selection and patient distribution according to no or 
mild versus moderate to severe cGVHD
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according to severity of cGVHD in both groups is shown 
in Fig. 2.
Pre‑transplantation factors associated with cGVHD
In the univariate analysis, we identified the following varia-
bles as risk factors for the development of moderate to severe 
cGVHD: presence of HLA antibodies in the patient before 
transplantation, graft composition with CD3+ cells ≥ 325 
 106/kg or CD19+ cells ≥ 82  106/kg. Multivariate Cox 
regression analysis confirmed HLA antibodies (P = 0.03, 
HR = 2.34, CI 95% 1.11–4.95), CD3+ cells in the graft ≥ 325 
 106/kg (P = 0.04, HR 2.18, CI 95% 1.04–4.59) and CD19+ 
cells in the graft ≥ 82  106/kg (P < 0.01, HR = 2.79, CI 95% 
1.35–5.74) as independent risk factors associated with the 
development of moderate to severe cGVHD (Table 3). Other 
factors including type of donor were not significantly associ-
ated with the severity of cGVHD in this cohort.
Comparing the clinical characteristics between patients 
according to the identified risk factors, there were no dif-
ferences among groups. In the group of patients with posi-
tive vs negative pre-transplant HLA antibodies (17 vs 81 
patients), median patient age was 54 (35–68) vs 56 years 
(24–74) (t(96) = 1,17, P = 0.24), median donor age was 40 
(20–66) vs 48 years (19–71) (t(96) = 1.88, P = 0.06), 76% vs 
86% received fludarabine/TBI as conditioning (P = 0.24) and 
90% in both groups received CsA/MMF as immunosuppres-
sion (P = 0.54). Nevertheless, 11 (65%) vs 27 (33%) patients 
developed moderate to severe cGVHD. The HLA antibod-
ies detected in these 17 patients were directed against HLA 
class I in 6 patients, against class HLA class II in 2 patients 
and against HLA class I and II in 9 patients. None of the 
patients with HLA antibodies had donor-specific antibodies.
Comparing the group of patients who received grafts 
with ≥ 325 vs < 325  106/kg CD3 + cells (24 vs 73 patients), 
median patient age was 58 (44–69) vs 55 years (24–74) 
(t(95) = − 1.16, P = 0.24), median donor age was 44 (20–69) 
vs 45 years (19–71) (t(33) = 0.28, P = 0.78), 75% vs 88% 
received fludarabine/TBI as conditioning (P = 0.19) and 
83% vs 91% received CsA/MMF as immunosuppression 
(P = 0.26). Nevertheless, 15 (63%) vs 22 (30%) patients 
developed moderate to severe cGVHD.
Comparing the group of patients who received grafts 
with ≥ 82 vs < 82  106/kg CD19 + cells (24 vs 71 patients), 
median patient age was 59 (44–69) vs 56 years (24–74) 
(t(93) = − 1.41, P = 0.16), median donor age was 47 (20–67) 
vs 45 years (19–71) (t(93) = 0.071, P = 0.48), 79% vs 86% 
received fludarabine/TBI as conditioning (P = 0.31) and 
96% vs 87% received CsA/MMF as immunosuppression 
(P = 0.22). Nevertheless, 16 (67%) vs 20 (28%) patients 
developed moderate to severe cGVHD.
Comparing treatment-related mortality (TRM) 3 years 
after AlloSCT between patients in the control group versus 
the group with moderate to severe cGVHD, we saw no sig-
nificant difference (15% vs 5%, P = 0.20). Transplantation-
related causes of death are described in Table 4.
Comparing the occurrence of relapse rate (RR) 3 years 
after AlloSCT, we found a significantly higher cumulative 
RR in patients in the control group versus patients with mod-
erate to severe cGVHD (30% vs 7%, P < 0.01). Six (10%) 
patients in the control group relapsed within 6 months with 
no acute or mild cGVHD, 3/60 (6%) patients relapsed within 
6 months with previous aGVHD, 1/60 (2%) relapsed within 
Fig. 2  Distribution of cGVHD 
severity according to organ 
involvement
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6 months with previous acute and mild cGVHD, the other 
(8%) patients relapsed after 6 months. In the moderate to 
severe group, two patients relapsed, after 11 months and 
3 years with moderate cGVHD. In our study, the group “no 
cGVHD and mild cGVHD” has a significantly higher relapse 
rate after 3 months and within 1 year after ALLOSCT com-
pared with the group who developed moderate to severe 
cGVHD. The high relapse rate in this group explains the 
higher mortality rate in the group “no cGVHD and mild 
cGVHD” versus “moderate to severe cGVHD” (appendix 
Table 2). If we analyzed which factors could explain this 
difference, we know that the distribution of patients accord-
ing to AML/MDS risk status by diagnosis and according to 
remission status before ALLOSCT (low—and intermediate 
risk versus poor—and very poor risk) did not differ between 
these 2 groups. Moreover, the conditioning regimen, 
Table 3  Variables related to 
the development of moderate to 
severe cGVHD
Total of infused cells boundaries were determined based on Q75 for all cells
HLA human leukocyte antigen, CMV cytomegalovirus, GVHD graft-versus-host disease
a HLA antibodies found prior to transplantation in the serum
Bold values indicate that statistical significance P < 0.05)
Risk factors Univariate Multivariate
HR 95% CI P HR 95% CI P
Patient age
 < 50 years 1
 ≥ 50 years 1.18 0.55–2.50 0.662
Donor age
 < 50 years 1
 ≥ 50 years 0.874 0.45–1.67 0.686
Blood transfusions
 < 76 1
 ≥ 76 0.38 0.09–1.61 0.192
HLA antibodies in the  recipienta
 HLA antibodies negative 1
 HLA antibodies positive 2.49 1.22–5.08 0.012 2.34 1.11–4.95 0.026
Donor/recipient CMV status
 Matched 1
 Mismatched 1.04 0.37–2.94 0.935
Donor/recipient gender
 Matched 1
 Female to male 1.80 0.93–3.48 0.081
Type of donor
 SIB 1
 MUD 1.36 0.72–2.59 0.342
DPB1
 Match 1
 Permissive 1.13 0.51–2.53 0.768
 Non-permissive 1.40 0.60–3.28 0.441
 Permissive/non-permissive 1.24 0.65–2.38 0.519
Infused cells in the recipient:
 CD3 + 106/kg < 325 1
 CD3 + 106/kg ≥ 325 3.06 1.56–6.00 0.001 2.18 1.04–4.59 0.040
 CD19 + 106/kg < 82 1
 CD19 + 106/kg≥ 82 3.77 1.93–7.37 0.000 2.79 1.35–5.74 0.005
 CD34 + 106/kg < 8.6 1
 CD34 + 106/kg ≥ 8.6 1.47 0.73–2.97 0.281
GVHD
 No acute GVHD 1
 Acute GVHD 0.84 0.42–1.66 0.612
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immunosuppression regimen and the type of donor did not 
differ between these 2 groups. Thus, the factors related with 
a high percentage of relapses in the group with no-GVHD 
may be related to early immunological factors (as activa-
tion of donor T cells, migration of donor immune cells into 
target organs and thymic injury) which avoid tolerance and 
therefore recognize residual leukemic cells avoiding relapses 
in patients who develop moderate to severe cGVHD [18].
Discussion
In this well-defined unselected series of patients diagnosed 
with AML and/or MDS who consecutively received a 
peripheral blood T-cell repleted NMA AlloSCT, moderate 
or severe chronic graft-versus-host disease was associated 
with high morbidity, hospital dependency and poor quality 
of life as compared to mild cGVHD [6, 7]. The goal of this 
study was to identify risk factors associated with severity, 
i.e., with the development of moderate to severe cGVHD in 
this population.
We identified 3 independent risk factors associated 
with the development of moderate to severe cGVHD: 
HLA antibodies in patient’s serum before transplantation, 
CD19+ ≥ 82  106/kg cells and/or CD3+ ≥ 325  106/kg cells 
in the graft.
Our results on the correlation of HLA antibodies with 
the severity of cGVHD are in accordance with a previ-
ously reported study [19]. Pan et al. described a correla-
tion between the presence in patients’ serum of antibodies 
against HLA before or in the 1st month after transplanta-
tion and cGVHD. They studied a cohort of patients diag-
nosed with hematological malignancies who received a 
BM/PBSCT with myeloablative conditioning. They found 
a higher rate of extensive cGVHD in the group with HLA 
antibodies in comparison to the group of patients without 
HLA antibodies prior to transplantation [19]. In our study, 
the HLA antibody status before transplantation was associ-
ated with the development of moderate to severe cGVHD. 
We know that pre-formed HLA antibodies prior to AlloSCT 
can be unaffected by standard transplantation conditioning 
regimens [20]. Broad sensitization against many HLA anti-
gens can occur when the immune system is only exposed to 
a single non-self HLA antigen, resulting in HLA antibodies 
that can react to more than one antigen (cross-reactivity) 
[21]. In a patient receiving allogeneic cells followed by a 
changing very active immune system, HLA antibody cross-
reactivity to non-self or auto-antigens could stimulate auto-
inflammatory reactions. Having identified HLA antibodies 
in patients before AlloSCT as risk factor for moderate to 
severe cGVHD, we hypothesize that the presence of HLA 
antibodies may indicate a state of high immune reactivity 
in patients, increasing the probability of triggering a more 
severe cGVHD.
We also identified the amount of infused CD19+ cells 
as a risk factor for the development of moderate to severe 
cGVHD. Recent studies demonstrated that B cells play an 
important role in the complex immuno-pathophysiology of 
cGVHD having an effector function, generating alloantibod-
ies and producing transforming growth factor beta [22–25]. 
Patients with cGVHD have high levels of B-cell-activating 
factor, present with increased survival of alloreactive- and 
auto-reactive B cells, and subvert the development of B-cell 
tolerance by attenuating B-cell receptor-triggered apoptosis 
of newly created polyreactive B cells [23, 24]. Moreover, a 
subtype of B cells (CD19+ CD21 low) has been found as an 
expanded population with features of exhaustion in patients 
with cGVHD and they have been correlated with severity of 
cGVHD [26]. These articles support the role of CD19+ cells 
as a parameter of severity in patients with cGVHD.
The correlation between the number of T cells in the 
graft with the incidence of moderate to severe cGVHD is in 
accordance with previously published studies [14, 27, 28]. 
These reports show a lower incidence of cGVHD in patients 
transplanted with BM as source of stem cells as compared to 
PB stem cells. Typically, PBSC grafts obtained using G-CSF 
for PBSC mobilization contain more T cells than BM grafts, 
resulting in a higher risk to develop GVHD [14, 27–30].
Our study has limitations that can explain why other 
expected risk factors as CMV serostatus and recipient gender 
were not found associated with the development of moderate 
to severe cGVHD [6, 31]. In our cohort, we did not focus 
on the development of global cGVHD, but we focussed on 
severity. A role of CMV serostatus as a risk factor for the 
development of moderate to severe cGVHD was not found. 
This could be explained by the fact that almost all donor/
recipients in our cohort had a positive CMV serostatus and 
therefore had no discriminating value. For female donor to 
male recipient transplantations, there was a trend towards a 
higher chance for moderate to severe cGVHD, but this did 
not reach statistical significance. We also did not find a role 
of previous aGVHD as a predictor for the development of 
moderate to severe cGVHD, as opposed to other studies [5, 
6]. A possible explanation may be early RR and TRM that 
Table 4  Transplantation-related causes of mortality





Sepsis 1 1 1




Treatment-resistant aGVHD 1 – –
Multi-organ failure 1 – 1
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occurred in the control group, resulting in a relatively high 
mortality rate within 6 months after transplantation. Nev-
ertheless, the association of the identified risk factors with 
severity of cGVHD has biological support and opens up the 
opportunity to be validated in a multi-center study.
In conclusion, we identified HLA antibodies in patients 
and number of CD19 + and/or CD3 + cells in the graft to 
be associated with the development of moderate to severe 
cGVHD in patients with AML or MDS who received a 
NMA AlloPBSCT. Our results should be confirmed in a 
larger multi-center cohort of patients to confirm clinical 
significance.
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